CO2023008272A2 - Métodos de tratamiento del lupus eritematoso cutáneo y lupus eritematoso sistémico - Google Patents

Métodos de tratamiento del lupus eritematoso cutáneo y lupus eritematoso sistémico

Info

Publication number
CO2023008272A2
CO2023008272A2 CONC2023/0008272A CO2023008272A CO2023008272A2 CO 2023008272 A2 CO2023008272 A2 CO 2023008272A2 CO 2023008272 A CO2023008272 A CO 2023008272A CO 2023008272 A2 CO2023008272 A2 CO 2023008272A2
Authority
CO
Colombia
Prior art keywords
lupus erythematosus
treatment methods
cutaneous
systemic lupus
systemic
Prior art date
Application number
CONC2023/0008272A
Other languages
English (en)
Inventor
Francois Gaudreault
Himanshu Naik
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of CO2023008272A2 publication Critical patent/CO2023008272A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan regímenes de dosificación de anticuerpos contra el antígeno de células dendríticas de la sangre 2 para el uso en el tratamiento del lupus eritematoso cutáneo y lupus eritematoso sistémico.
CONC2023/0008272A 2020-12-03 2023-06-23 Métodos de tratamiento del lupus eritematoso cutáneo y lupus eritematoso sistémico CO2023008272A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063121194P 2020-12-03 2020-12-03
PCT/US2021/061764 WO2022120144A1 (en) 2020-12-03 2021-12-03 Methods of treating cutaneous lupus erythematosus and systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
CO2023008272A2 true CO2023008272A2 (es) 2023-09-29

Family

ID=79024222

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0008272A CO2023008272A2 (es) 2020-12-03 2023-06-23 Métodos de tratamiento del lupus eritematoso cutáneo y lupus eritematoso sistémico

Country Status (15)

Country Link
US (1) US20240018246A1 (es)
EP (1) EP4255392A1 (es)
JP (1) JP2024501430A (es)
KR (1) KR20230119664A (es)
CN (1) CN116963716A (es)
AR (1) AR124247A1 (es)
AU (1) AU2021391803A1 (es)
CA (1) CA3203971A1 (es)
CL (1) CL2023001562A1 (es)
CO (1) CO2023008272A2 (es)
IL (1) IL303279A (es)
MX (1) MX2023006474A (es)
PE (1) PE20231678A1 (es)
TW (1) TW202222829A (es)
WO (1) WO2022120144A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2280264T3 (es) * 1999-11-15 2007-09-16 Miltenyi Biotec Gmbh Fragmentos de union a antigeno especificos de celulas dendriticas, composiciones y metodos de uso de los mismos, antigenos reconocidos y celulas asi obtenidas.
US9902775B2 (en) * 2012-12-10 2018-02-27 Biogen Ma Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof
EP3088519A4 (en) * 2013-12-24 2017-09-13 Astellas Pharma Inc. Novel anti-human bdca-2 antibody
MA44763A (fr) * 2016-04-28 2019-03-06 Biogen Ma Inc Compositions pharmaceutiques et régimes posologiques destinés à une utilisation clinique d'anticorps anti-antigène 2 de cellules dendritiques du sang

Also Published As

Publication number Publication date
CN116963716A (zh) 2023-10-27
KR20230119664A (ko) 2023-08-16
CA3203971A1 (en) 2022-06-09
TW202222829A (zh) 2022-06-16
IL303279A (en) 2023-07-01
AU2021391803A1 (en) 2023-07-06
JP2024501430A (ja) 2024-01-12
CL2023001562A1 (es) 2023-12-15
MX2023006474A (es) 2023-08-16
EP4255392A1 (en) 2023-10-11
WO2022120144A1 (en) 2022-06-09
AR124247A1 (es) 2023-03-01
AU2021391803A9 (en) 2024-09-26
PE20231678A1 (es) 2023-10-19
US20240018246A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
EA202091333A1 (ru) Способы активации, модификации и экспансии t-клеток для лечения рака и связанных с ним злокачественных заболеваний
DOP2019000280A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
CL2018002763A1 (es) Moléculas de unión a bcma y métodos de uso de las mismas.
CL2019001568A1 (es) Un acoplador biespecifico de células t que comprende un primer dominio que se une a la región constante de tcr beta 1 (trbc1) o trbc2, y un segundo dominio capaz de activar una célula t. (divisional solicitud 201803096)
BR112022002708A2 (pt) Nanopartículas lipídicas aperfeiçoadas para a liberação de ácidos nucleicos
CO2018012506A2 (es) Composiciones farmacéuticas y regímenes de dosificación para el uso clínico de anticuerpos contra el antígeno 2 de las células dendríticas de la sangre
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CL2021001542A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (divisional de la solicitud no. 201800324)
AR110645A1 (es) Anticuerpos anti-hla-g y uso de los mismos
CL2018001334A1 (es) Anticuerpos y conjugados anticuerpo-fármaco anti-5t4.
ES2981569T3 (es) Métodos de tratamiento usando terapia celular adoptiva
PE20161217A1 (es) Anticuerpos anti-cd3 y metodos de uso
ECSP21052194A (es) Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
SV2018005730A (es) Biomarcadores para copanlisib
CL2021001260A1 (es) Anticuerpos anti-sirpa humanizados
UY38889A (es) Inmunocitoquina que comprende un complejo de proteína heterodimérico basado en il-15/il-15r¿ y su uso
CU20210003A7 (es) Una preparación farmacéutica liposomal de mitoxantrona útil en el tratamiento de linfoma no de hodgkin
CL2021001201A1 (es) Métodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn
MX2020004910A (es) Composiciones y métodos para el agotamiento de células cd5 +.
AR084263A1 (es) Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen)
AR109279A1 (es) Anticuerpos anti plazomicina y métodos de uso de los mismos
CO2023008272A2 (es) Métodos de tratamiento del lupus eritematoso cutáneo y lupus eritematoso sistémico
BR112023002926A2 (pt) Agentes terapêuticos inaláveis
BR112022015447A2 (pt) Métodos para o tratamento de escleroderma e condições relacionadas
BR112022009587A2 (pt) Anticorpo anti-pcsk9 e uso do mesmo